EUVIMEDEUVIMED entdecken
Open Access

Biomarker Testing Disparities in Metastatic Colorectal Cancer

Saad Sabbagh, María Herrán, Ali Hijazi, Iktej Singh Jabbal, Mohamed Mohanna, Barbara Dominguez, Mira Itani, Kaylee Sarna, Hong Liang, Zeina Nahleh, Steven D Wexner, Arun Nagarajan

JAMA Network Open · 05.07.2024 · 7 (7) · e2419142

DOI: 10.1001/jamanetworkopen.2024.19142 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 05.07.2024. Verfasst von Saad Sabbagh und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology-Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Biomarkers, Tumor, Microsatellite Instability, Healthcare Disparities. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Among patients with metastatic colorectal cancer (mCRC), data are limited on disparate biomarker testing and its association with clinical outcomes on a national scale.

Objective

To evaluate the socioeconomic and demographic inequities in microsatellite instability (MSI) and KRAS biomarker testing among patients with mCRC and to explore the association of testing with overall survival (OS). Design, Setting, and Participants This cohort study, conducted between November 2022 and March 2024, included patients who were diagnosed with mCRC between January 1, 2010, and December 31, 2017. The study obtained data from the National Cancer Database, a hospital-based cancer registry in the US. Patients with mCRC and available information on biomarker testing were included. Patients were classified based on whether they completed or did not complete MSI or KRAS tests. Exposure Demographic and socioeconomic factors, such as age, race, ethnicity, educational level in area of residence, median household income, insurance type, area of residence, facility type, and facility location were evaluated. Main Outcomes and Measures The main outcomes were MSI and KRAS testing between the date of diagnosis and the date of first-course therapy. Univariable and multivariable logistic regressions were used to identify the relevant factors in MSI and KRAS testing. The OS outcomes were also evaluated.

Results

Among the 41 061 patients included (22 362 males [54.5%]; mean [SD] age, 62.3 [10.1] years; 17.3% identified as Black individuals, 78.0% as White individuals, 4.7% as individuals of other race, with 6.5% Hispanic or 93.5% non-Hispanic ethnicity), 28.8% underwent KRAS testing and 43.7% received MSI testing. A significant proportion of patients had Medicare insurance (43.6%), received treatment at a comprehensive community cancer program (40.5%), and lived in an area with lower educational level (51.3%). Factors associated with a lower likelihood of MSI testing included age of 70 to 79 years (relative risk [RR], 0.70; 95% CI, 0.66-0.74; P < .001), treatment at a community cancer program (RR, 0.74; 95% CI, 0.70-0.79; P < .001), rural residency (RR, 0.80; 95% CI, 0.69-0.92; P < .001), lower educational level in area of residence (RR, 0.84; 95% CI, 0.79-0.89; P < .001), and treatment at East South Central facilities (RR, 0.67; 95% CI, 0.61-0.73; P < .001). Similar patterns were observed for KRAS testing. Survival analysis showed modest OS improvement in patients with MSI testing (hazard ratio, 0.93; 95% CI, 0.91-0.96; P < .001). The median (IQR) follow-up time for the survival analysis was 13.96 (3.71-29.34) months. Conclusions and Relevance This cohort study of patients with mCRC found that older age, community-setting treatment, lower educational level in area of residence, and treatment at East South Central facilities were associated with a reduced likelihood of MSI and KRAS testing. Highlighting the sociodemographic-based disparities in biomarker testing can inform the development of strategies that promote equity in cancer care and improve outcomes for underserved populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsBiomarkers, TumorMicrosatellite InstabilityHealthcare DisparitiesProto-Oncogene Proteins p21(ras)HumansMaleFemaleMiddle AgedAgedUnited StatesCohort StudiesSocioeconomic FactorsNeoplasm Metastasis

Substanzen

Biomarkers, TumorProto-Oncogene Proteins p21(ras)KRAS protein, human

Autor:innen und Institutionen

  • Department of Hematology-Oncology, Maroone Cancer Center, Cleveland Clinic Florida, Weston.
  • Department of Internal Medicine, Advent Health Sebring, Sebring, Florida.
  • Department of Clinical Research, Cleveland Clinic Florida, Weston.
  • Ellen Leifer Shulman and Steven Shulman Digestive Disease Center, Cleveland Clinic Florida, Weston.

Zitieren

APA

Sabbagh, S., Herrán, M., Hijazi, A., Jabbal, I. S., Mohanna, M., Dominguez, B., Itani, M., Sarna, K., Liang, H., Nahleh, Z., Wexner, S. D., & Nagarajan, A. (2024). Biomarker Testing Disparities in Metastatic Colorectal Cancer. JAMA Network Open, 7(7), e2419142. https://doi.org/10.1001/jamanetworkopen.2024.19142

Vancouver

Sabbagh S, Herrán M, Hijazi A, Jabbal IS, Mohanna M, Dominguez B, et al. Biomarker Testing Disparities in Metastatic Colorectal Cancer. JAMA Network Open. 2024;7(7):e2419142. doi:10.1001/jamanetworkopen.2024.19142

BibTeX
@article{Sabbagh2024,
  author = {Sabbagh, Saad and Herrán, María and Hijazi, Ali and Jabbal, Iktej Singh and Mohanna, Mohamed and Dominguez, Barbara and Itani, Mira and Sarna, Kaylee and Liang, Hong and Nahleh, Zeina and Wexner, Steven D and Nagarajan, Arun},
  title = {Biomarker Testing Disparities in Metastatic Colorectal Cancer},
  journal = {JAMA Network Open},
  year = {2024},
  volume = {7},
  number = {7},
  pages = {e2419142},
  doi = {10.1001/jamanetworkopen.2024.19142}
}
Kostenlos starten →